Skip to content
value.today

AmplifyBio, LLC

🇺🇸 West Jefferson, Ohio, USABiotechnologyFounded 2021
Total raised
$230 M
3 rounds on record
Latest round
$50 M
Oct 2023
First round on record
Apr 2021
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of AmplifyBio, LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2023$50 MNo. 3$10 to $50 million

AmplifyBio, LLC: Raise no. 3, Oct 2023

Investors in this round

4 investors had bought by the notice of Nov 15, 2023: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$50 M of $100 M offered; $50 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • James Kelly Ganjei · Executive Officer
  • Lewis Kelly Von Thaer · Director
  • Matt Kelly Vaughan · Director
  • Rohan Kelly Nirody · Director
  • Shaun Kelly Rodriguez · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds will be used for working capital, which may include normal compensation to executive officers.”

Signed by J. Kelly Ganjei, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 15, 2023. Read the notice at the SEC.

equitySEC
Apr 2022$100 MNo. 2$50 to $250 million

AmplifyBio, LLC: Raise no. 2, Apr 2022

Investors in this round

8 investors had bought by the notice of Jun 29, 2022: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$100 M of $100 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • James Kelly Ganjei · Executive Officer
  • Lewis Kelly Von Thaer · Director
  • Matt Kelly Vaughan · Director
  • Rohan Kelly Nirody · Director
  • Shaun Kelly Rodriguez · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds will be used for working capital, which may include normal compensation to executive officers.”

Signed by J. Kelly Ganjei, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 29, 2022. Read the notice at the SEC.

equitySEC
Apr 2021$80 MNo. 1$50 to $250 million

AmplifyBio, LLC: Raise no. 1, Apr 2021

Investors in this round

3 investors had bought by the notice of May 27, 2021: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$80 M of $80 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Kelly J. Ganjei · Executive Officer
  • Russell J. Austin · Director, Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds will be used for working capital, which may include normal compensation to executive officers.”

Signed by J. Kelly Ganjei, Chief Executive Officer. Source: SEC Form D, newest notice filed May 27, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • AmplifyBio, LLC chose not to state its revenue in its newest notice of a funding round (Nov 2023).

    SEC Form D · Nov 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2023

That is all the official record says: AmplifyBio, LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of AmplifyBio, LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 8 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by AmplifyBio, LLC
NameRoleNamed in
James Kelly GanjeiExecutive officerNov 2023
Kelly J. GanjeiExecutive officerMay 2021
Lewis Kelly Von ThaerDirectorNov 2023
Matt Kelly VaughanDirectorNov 2023
Rohan Kelly NirodyDirectorNov 2023
Shaun Kelly RodriguezDirectorNov 2023
Russell J. AustinDirectorMay 2021
Russell J. AustinPromoterMay 2021